德琪医药亮相“格隆汇·中期策略会·2025”，空间位阻遮蔽技术TCE平台第一股大放异彩

Core Viewpoint - 德琪医药 is showcasing its strength as an innovative biopharmaceutical company with a focus on developing breakthrough therapies to improve patient survival quality globally, particularly in oncology and autoimmune diseases [1]. Group 1: Company Performance - 德琪医药's stock price has surged over 347.69% year-to-date as of June 30, 2025, reflecting strong market performance driven by its innovative drug pipeline [1][4]. - The company has a robust research and development pipeline, including a second-generation TCE platform and late-stage global assets, which are expected to provide long-term growth momentum [5]. Group 2: Innovative Technology - The AnTenGager™ platform, a new second-generation "2+1" TCE technology, enhances safety and efficacy through spatial steric shielding, reducing the risk of cytokine release syndrome (CRS) and expanding targeting capabilities [8]. - The platform's advantages include improved safety, expanded targeting ability for low-expressing antigens, broad applicability across various cancers and autoimmune diseases, and a strong patent barrier due to unique antibody sequences [8][9]. Group 3: Key Products - ATG-022 (Claudin 18.2 ADC) is advancing in clinical trials, with a peak sales potential estimated at $5 billion, demonstrating significant efficacy in both high and low expression patient populations [10][14]. - ATG-037, an oral CD73 small molecule, is set to enter Phase II clinical trials, showing promising results in combination with KEYTRUDA® for melanoma patients resistant to immune checkpoint inhibitors [15]. Group 4: Strategic Initiatives - 德琪医药 has initiated an open strategy for the AnTenGager™ platform, focusing on technology licensing, joint development, and product authorization to maximize platform value [9]. - The company is actively pursuing a dual model of business development and licensing cooperation to sustain growth momentum in the future [9].